Why the study?
Does tailored antiplatelet therapy reduce the composite of death and stent thrombosis in antiplatelet-resistant patients?
Population
7 randomized studies comprising 12,048 subjects, of whom 3,738 (31.0%) were antiplatelet-resistant
Comparison
Tailored antiplatelet therapy vs Conventional antiplatelet treatment
Design
Meta-analysis
Authors
Loading...
Tailored antiplatelet therapy may be considered in resistant patients to lower death or thrombosis; confirms substantial benefit in Level 1 meta-analysis.
Does tailored antiplatelet therapy reduce the composite of death and stent thrombosis in antiplatelet-resistant patients?
Tailored antiplatelet therapy significantly reduces the risk of death or stent thrombosis and total clinical adverse events in antiplatelet-resistant patients without increasing bleeding risk.
Li et al. (2013) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: